[Clinical research of xinganbao capsule on the treatment of chronic hepatitis B liver fibrosis]

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012 Mar;32(3):325-8.
[Article in Chinese]


Objective: To explore the effects of Xinganbao Capsule (Cordyceps Sinensis) on the chronic hepatitis B liver fibrosis.

Methods: Sixty patients with chronic hepatitis B were randomly assigned to the trail group (40 cases) and the control group (20 cases). The trail group was treated with Xinganbao Capsule, 8 capsules each time, three times a day. The control group was given Heluo Shugan Tablet, 5 pills each time, thrice daily. Six months consisted of one therapeutic course. The liver function, four indicators of serum fibrosis, liver histology, and other items were detected.

Results: Xinganbao Capsule could reduce serum ALT and AST levels, serum HA, PC-III and LN levels (all P<0.05), showing statistical difference when compared with before treatment. The HA and LN levels decreased more significantly in the control group when compared with before treatment (P<0.05). Totally 21 patients (53% of the recruited cases) in the trial group completed the liver biopsy twice. After treated with Xinganbao Capsule, 81% patients (17/21) had decreased liver inflammation 1 grade or more, 52% patients (11/21) had decreased fibrosis staging one or more, and 33% (7/21) patients had no change in fibrosis.

Conclusion: Xinganbao Capsule could improve the liver function, reduce liver inflammation, and fight against hepatic fibrosis.

Publication types

  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Drugs, Chinese Herbal / therapeutic use*
  • Female
  • Hepatitis B, Chronic / drug therapy*
  • Hepatitis B, Chronic / pathology
  • Humans
  • Liver Cirrhosis / drug therapy*
  • Liver Cirrhosis / pathology
  • Male
  • Middle Aged
  • Phytotherapy*
  • Treatment Outcome


  • Drugs, Chinese Herbal